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Abstract We investigated in vitro effects of recombinant human 
thrombopoietin (TPO), or c-Mpl ligand, on human platelets. 
TPO induced rapid dose-dependent tyrosine phosphorylation of 
several proteins. We identified Janus tyrosine kinases, Tyk2 and 
JAK2, and a member of STAT (signal transducers and activators 
of transcription) family, STAT3, as the tyrosine-phosphorylated 
proteins in response to TPO. TPO by itself did not cause platelet 
aggregation and shape change, but augmented ADP-indnced ag- 
gregation in a dose-dependent manner. Acetyisalicylic acid inhib- 
ited the secondary aggregation enhanced by TPO, but not the 
TPO-induced potentiation of the primary aggregation. TPO 
modulates platelet activation possibly through protein-tyrosine 
phosphorylation. 
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I. Introduction 
Many previous studies have suggested that lineage-specific 
humoral factors regulate platelet production [1]. Recently, sev- 
eral groups [2-5] cloned the ligand for the c-Mpl proto-onco- 
gene [6] which is a member of the cytokine receptor superfa- 
mily. These studies and others have demonstrated that c-Mpl 
ligand plays a critical role in megakaryocytopoiesis and throm- 
bopoiesis both in vitro and in vivo [2-5,7-10]. Therefore, c-Mpl 
ligand has been termed thrombopoietin (TPO) [3,7,8] or 
megakaryocyte growth and development factor (MGDF) [4]. 
The cytokine receptor superfamily, which lacks a tyrosine ki- 
nase domain, couples ligand binding with the induction of pro- 
tein-tyrosine phosphorylation that is essential for cytokine sig- 
naling [11]. The Janus tyrosine kinase (JAK) family, JAK1, 
JAK2, JAK3, and Tyk2, and the STAT (for signal transducers 
and activators of transcription) family are activated through 
phosphorylation on tyrosine in response to cytokines and 
growth factors [12,13]. JAKs and STATs provide novel com- 
mon pathways hared by the receptors for various cytokines or 
growth factors. Some researchers [14-17] have reported that 
TPO stimulates tyrosine phosphorylation of molecules includ- 
ing JAK2 and STATs in megakaryocytic cell lines or cells 
engineered to express the c-Mpl. 
*Corresponding author. Fax: (81) (75) 751-3201. 
Abbreviations." TPO, thrombopoietin; JAK, Janus tyrosine kinase; 
ASA, acetylsalicylic acid or aspirin; PRP, platelet-rich plasma; STAT, 
signal transducers and activators of transcription. 
A very recent report has shown that c-Mpl is expressed in 
megakaryocytic l neage from late progenitors to platelets [18]. 
Another study showed that TPO enhances ADP-induced plate- 
let aggregation and that this activation is blocked by acetylsal- 
icylic acid, aspirin, (ASA) [19]. In the present study we investi- 
gated in vitro effect of recombinant human TPO on human 
platelets. Our findings indicated that TPO stimulated tyrosine 
phosphorylation of several proteins including the JAK and 
STAT families, and possessed ASA-insensitive potentiation ef- 
fect on platelet aggregation. 
2. Materials and methods 
2.1. Reagents 
Recombinant human TPO was a kind gift from Kirin Brewery Co. 
(Maebashi, Japan). Anti-phosphotyrosine mAb 4G10 and rabbit anti- 
STAT2 polyclonal antibody were purchased from Upstate Biotechnol- 
ogy Inc. (Lake Placid, NY). Affinity-purified rabbit polyclonal anti- 
bodies against JAK1 (HR-785), JAK2 (HR-758), JAK3 (C-21), Tyk2 
(C-20), STAT3 (C-20), and STAT4 (C-20) were obtained from Santa 
Cruz Biotechnology Inc. (Santa Cruz, CA). Anti-STATlcdfl mAb (C- 
136) recognizes both STATlc~ and -lfl, and was obtained from Santa 
Cruz Biotechnology. Anti-STAT5 and anti-STAT6 mAbs were from 
Transduction Laboratories (Lexington, KY). Affinity-purified rabbit 
anti-mouse IgG was obtained from Organon Teknika Corp. (Durham, 
NC). PGE~ was kindly provided by Ono Pharmaceutical Co. (Osaka, 
Japan). Sodium arachidonate was purchased from Nu-Chek Prep. Inc. 
(Elysian, MN). Apyrase, ADP, and human fibrinogen were purchased 
from Sigma. All other reagents were obtained as previously described 
[20]. 
2.2. Platelet preparation 
After informed consent was obtained, venous blood was collected 
from healthy adult donors who denied having taken any drugs for at 
least two weeks prior to the donation. Anti-coagulation f blood with 
acid/citrate/dextrose anticoagulant and preparation of platelet-rich 
plasma (PRP) were performed as described previously [21]. PRP was 
incubated with 1 mM ASA for 30 min at 37°C. Gel-filtered platelets 
were prepared as described by Tangen et al. [22] and finally suspended 
at a concentration f 1 z 10 9 cells/ml in HEPES buffer (137 mM NaCI, 
2.7 mM KCI, 1 mM MgCI2, 1 mM CaCI2, 5.6 mM glucose, 1 mg/ml 
BSA, 3.3 mM NaH~PO4, and 20 mM HEPES, pH 7.4). 
2.3. lmmunoprecipitation, immunoblotting, and in vitro kinase assays 
Gel-filtered ASA-treated platelets were incubated with or without 
various concentrations of TPO for appropriate periods at 37°C. Fol- 
lowing the TPO treatment, platelets were lysed for 1 h in a half-volume 
of 3 z lysis buffer (150 mM NaC1, 15 mM EGTA, 3% Triton X-100, 3% 
sodium deoxycholate, 0.3% SDS, 3 mM PMSF, 3 mM Na3VO4, 60 
¢tg/ml eupeptin, 60 ¢tg/ml aprotinin, and 50 mM Tris-HC1, pH 7.4). 
This and all subsequent steps were carried out at 4°C. For preparation 
of whole platelet lysates, the extracts were centrifuged at10,000 xg for 
30 rain, diluted with an equal volume of 2 x Laemmli SDS sample 
buffer, and boiled for 5 min. Immunoprecipitation f r JAKs and 
STATs was done as previously described [20], using 5 ¢tg/ml antibodies 
specific for each protein and rabbit anti-mouse IgG as a control. 
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Immunoprecipitated proteins were eluted with SDS sample buffer and 
boiled for 5 min. The samples (the whole platelet lysates from 6 x 106 
cells/lane orthe immunoprecipitates from 2.6 x 108 cells/lane) were sub- 
jected to 8% SDS-PAGE and transferred electrophoretically to a nitro- 
cellulose membrane (Bio-Rad, Hercules, CA) with a semidry blotter. 
The membranes were treated for immunoblot assay as described previ- 
ously [20]. To detect phosphotyrosine-containing proteins, the mem- 
branes were incubated with a mAb 4G10 (1 ¢tg/ml). For detection of 
JAKs and STATs, antibodies (1pg/ml) against each protein were used 
as the primary antibodies. In some xperiments, he membranes once 
probed were stripped of bound antibodies and reprobed with other 
antibodies. In vitro kinase activity of immunoprecipitated JAKs was 
determined aspreviously described [23]. 
2.4. Platelet aggregometry 
PRP was prepared from five different volunteers as described above 
with 0.38% sodium citrate instead of acid/citrate/dextrose anticoagu- 
lant. PRP was adjusted at a concentration f 2 × 108 cells/ml and incu- 
bated with or without 1 mM ASA for 30 min at 37°C before aggregom- 
etry. Gel-filtered platelets suspended at a concentration f 3 x 108 cells/ 
ml in HEPES buffer were also prepared as described above. Standard 
aggregometory f PRP or gel-filtered platelets with 100/,tg/ml human 
fibrinogen was performed in an aggregometer (HEMA TRACER 1, 
Nikko Bioscience, Tokyo, Japan). 
3. Results 
3.1. Induction of protein-tyrosine phosphorylation by 
recombinant human TPO in human platelets 
We first investigated the effect of TPO on tyrosine phospho- 
rylation of platelet proteins in vitro. With anti-phosphotyrosine 
immunoblot, we found that TPO treatment ofgel-filtered plate- 
lets induced tyrosine phosphorylation f several proteins in a 
concentration- and time-dependent manner (Fig. 1A,B). When 
platelets were exposed to various concentrations of TPO for 
3 rain, 125-, 98-, and 94/92-kDa tyrosine-phosphorylated pro-
tein bands were detected at a minimal concentration f 2 ng/ml 
and their intensity reached the maximum at 50 ng/ml (Fig. 1A). 
Interestingly, among the tyrosine-phosphorylated proteins in 
resting platelets, the phosphotyrosine content of 64-kDa pro- 
tein band was increased by TPO treatment. Following exposure 
to 50 ng/rnl TPO, tyrosine phosphorylation f these proteins 
peaked at 2-5 rain and slightly diminished at 20 min (Fig. 1B). 
312. Tyrosine phosphorylation of JAK family kinases, Tyk2 and 
JAK2, induced by TPO in platelets 
We examined tyrosine phosphorylation of four members 
(Tyk2, JAK1, JAK2, anad JAK3) of the JAK family. Using 
immunoprecipitation and immunoblotting techniques, we de- 
tected all four JAK kinases in platelets (Fig. 2b). The exposure 
of platelets to TPO yielded tyrosine phosphorylation f Tyk2 
(135 kDa) and JAK2 (125 kDa), but not JAKI (130 kDa) and 
JAK3 (115 kDa) (Fig. 2a). TPO-induced tyrosine phosphoryla- 
tion of both Tyk2 and JAK2 were detected at 30 s following 
TPO (50 ng/ml) treatment, peaked at 2 5 min, and slightly 
diminished at 20 min (Fig. 3Aa and 3Ba). As it is generally 
accepted that tyrosine phosphorylation f JAKs is associated 
with the activation of kinase activity [13,23], TPO treatment 
increased in vitro kinase activity of Tyk2 and JAK2 in parallel 
with tyrosine phosphorylation of these kinases (data not 
shown). 
3.3. Tyrosine phosphorylation of STAT3 induced by TPO in 
platelets 
We examined whether TPO induced tyrosine phosphoryla- 
tion of STATs in platelets. As shown in Fig. 4Ab, we identified 
STATlc~ (91 kDa), STAT2 (113 kDa), and STAT3 (92 kDa). 
Also, we further detected STAT5 and STAT6, but did neither 
STATlfl nor STAT4 (data not shown). Among them, incuba- 
tion of platelets with TPO (50 ng/ml) for 3 min resulted in 
tyrosine phosphorylation f STAT3 (Fig. 4Aa). Following TPO 
exposure, phosphorylation f STAT3 on tyrosine was detected 
at 1 min, peaked at 5 rain, and slightly diminished at 20 min 
(Fig. 4Ba). The kinetics of tyrosine phosphorylation f STAT3 
was somewhat slower than those of Tyk2 and JAK2 (Fig. 
3A,B). 
3.4. TPO-induced ASA-insensitive enhancement ofplatelet 
aggregation 
Hammond et al. have recently reported that TPO potentiates 
ADP-induced platelet aggregation and that this activation of 
platelet function can be blocked by ASA, suggesting that TPO 
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Fig. 1. Dose- and time-dependent tyrosine phosphorylation induced by 
TPO in platelets. Gel-filtered platelets were incubated with TPO at the 
indicated concentrations (A) or 50 ng/ml (B), for 3 rain (A) or various 
periods (B). Platelet lysates were subjected to SDS-PAGE and im- 
munoblotted with anti-phosphotyrosine a tibody. Molecular mass 
markers are indicated in kDa. 
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Fig. 2. TPO-induced tyrosine phosphorylation f JAK family kinases. 
Gel-filtered platelets were incubated with (+) or without (-) 50 ng/ml 
TPO for 3 rain and immunoprecipitated with antibodies against JAK 1, 
JAK2, JAK3, and Tyk2, or rabbit anti-mouse IgG (RAM) as a control. 
The immunoprecipitates were subjected to SDS-PAGE and im- 
munoblotted with anti-phosphotyrosine antibody (a). The im- 
munoblots were then stripped and reprobed with the same antibodies 
as used for immunoprecipitation (b). Molecular mass markers are indi- 
cated in kDa. 
potentiates platelet function in an ASA-sensitive way [19]. 
Therefore, we examined the effects of TPO on platelet function 
and compared them between ASA-treated and -untreated 
platelets. TPO by itself did not induce either platelet aggrega- 
tion or shape change at concentrations up to 1000 ng/ml tested 
(data not shown). As shown in Fig. 5A, traces a and b, the 
addition of 5/aM ADP into PRP caused only the primary 
aggregation which was not affected by ASA treatment. When 
ASA-untreated platelets were preincubated with 5 ng/ml TPO 
for 3 rain and stimulated by 5/aM ADP, TPO enhanced the 
stimulatory effect of ADP leading to irreversible aggregation 
(Fig. 5A, trace e). ASA treatment completely abolished the 
potentiation effect of 5 ng/ml TPO on 5 /aM ADP-induced 
platelet aggregation (Fig. 5A, trace c), confirming the findings 
by Hammond et al. However, when platelets were preincubated 
with 20 ng/ml TPO prior to 5/aM ADP stimulation, ASA 
treatment failed to change the aggregation curve by the stimu- 
lation of TPO plus ADP into that by ADP stimulation alone 
(Fig. 5A, traces b, d and f). On the other hand, ASA treatment 
completely abolished 2 mM arachidonate-induced aggregation 
(data not shown). These suggested to us that TPO at relatively 
higher concentrations could enhance the primary aggregation, 
which was characterized by disaggregation a d insensitive to 
ASA treatment. Therefore, we focused on the effects of TPO 
on the primary aggregation. In order to ensure the primary 
aggregation alone, platelets were stimulated by low concentra- 
tions of ADP or pretreated by ASA (Fig. 5B). Whether platelets 
were aspirinized or not, pretreatment of platelets with 50 ng/ml 
TPO resulted in the enhancement of 1/aM ADP-induced pri- 
mary aggregation (Fig. 5B, traces a and b). Likewise, 50 ng/ml 
TPO enhanced 5 or 10/aM ADP-induced primary aggregation 
of aspirinized platelets (Fig. 5B, traces c-f). The potentiation 
effect on the primary aggregation i duced by 5/aM ADP was 
dependent on TPO concentrations (Fig. 5, traces c and d in 
panel A, and trace e in panel B). This dose-dependency of TPO 
effect was confirmed also by various ADP concentrations up 
to I0/aM, and a concentration of 200 ng/ml TPO elicited the 
maximal potentiation effect on the primary aggregation (data 
not shown). The ASA-insensitive enhancement of aggregation 
by TPO was also observed in the experiments u ing epinephrine 
or collagen as agonists (Y. Ezumi, H. Takayama, and M. 
Okuma, unpublished observations). Furthermore, essentially 
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similar results described above were obtained from the experi- 
ments using gel-filtered platelets in the presence of fibrinogen 
(data not shown). 
4. Discussion 
Recently, many investigators have reported that protein-ty- 
rosine phosphorylation plays a critical role in the signal 
transduction through ligand binding to the cytokine receptor 
superfamily, including c-Mpl [11,14-17,24]. First, we studied 
tyrosine-phosphorylated proteins in ASA-treated platelets ex- 
posed to TPO. Although, we confirmed that TPO induced rapid 
tyrosine phosphorylation f several proteins including JAK2 in 
platelets as previously reported by Miyakawa et al. [24], the 
present work is the first report demonstrating that TPO stimu- 
lated tyrosine phosphorylation a d kinase activity of Tyk2 in 
platelets. We also identified for the first time STAT family 
members, STATI~, STAT2, STAT3, STAT5, and STAT6, in 
platelets and demonstrated that TPO stimulated tyrosine phos- 
phorylation of STAT3. Very recent studies have shown that 
TPO activates STAT1, STAT3, or STAT5 in several cell llines 
[15 17]. Since platelets are terminal-differentiated anuclear 
cells, it is tempting to speculate that tyrosine-phosphorylated 
STAT3 could play a different role in platelets from the roles in 
other cells reported previously. Other signaling molecules in 
platelets may interact with STAT3, which has SH2 and SH3 
domains and is tyrosine-phosphorylated. 
It has been recently reported in an abstract form by Ham- 
mond et al. that TPO enhances platelet aggregation i duced by 
ADP and that ASA blocks this activation [19]. We confirmed 
that ADP-induced platelet aggregation was enhanced by TPO. 
Their report seems to agree with our findings that ASA inhib- 
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Fig. 3. Time course of TPO-induced tyrosine phosphorylation f Tyk2 
and JAK2. Gel-filtered platelets were incubated with 50 ng/ml TPO for 
the indicated periods and immunoprecipitated with anti-Tyk2 (A) or 
anti-JAK2 (B) antibodies. Immunoprecipitates were subjected to SDS- 
PAGE and immunoblotted with anti-phosphotyrosine a tibody (a in 
panels A and B). The immunoblots were then stripped and reprobed 
with anti-Tyk2 (b in panel A) or anti-JAK2 (b in panel B) antibodies. 
Arrows mark the positions of Tyk2 and JAK2. 
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Fig. 4. TPO-induced tyrosine phosphorylation of STAT3. (A) Gel- 
filtered platelets were incubated with (+) or without (-) 50 ng/ml TPO 
for 3 min and immunoprecipitated with antibodies against STATlcdfl, 
STAT2, and STAT3. The immunoprecipitates w re subjected to SDS- 
PAGE and immunoblotted with anti-phosphotyrosine antibody (a). 
The immunoblots were then stripped and reprobed with the same anti- 
bodies as used for immunoprecipitation (b). Molecular mass markers 
are indicated in kDa. (B) Gel-filtered platelets were incubated with 50 
ng/ml TPO for the indicated periods and immunoprecipitated with 
anti-STAT3 antibody. Immunoprecipitates were subjected to SDS- 
PAGE and immunoblotted with anti-phosphotyrosine antibody (a). 
The immunoblots were then stripped and reprobed with anti-STAT3 
antibody (b). Arrows mark the position of STAT3. 
ited the irreversible secondary aggregation enhanced by TPO. 
However, at higher concentrations of TPO than 5 ng/ml, we 
found that TPO enhanced the primary aggregation, which was 
characterized by disaggregation a d insensitive to ASA treat- 
ment, although the secondary aggregation was still inhibited by 
ASA. This ASA-insensitive potentiation effect of TPO on the 
primary aggregation was dose-dependent irrespective of ADP 
concentrations used. Such observations were also obtained 
with other agonists, collagen or epinephrine, than ADR Thus, 
we demonstrated for the first time that TPO potentiated platelet 
aggregation i an ASA-insensitive way. 
There are several pieces of evidence for the modulation of in 
vitro platelet function by other cytokines or growth factors. 
IL-lfl and IFN-y enhance the adhesion of thrombin-treated 
platelets to monocytic leukemia cells, U937, and the release of 
serotonin by thrombin [25]. G-CSF augments the secondary 
aggregation of platelets induced by ADP [26]. PDGF inhibited 
collagen- or thrombin-induced aggregation [27] and secretion 
of ADP or fl-hexosaminidase in an autocrine manner [28]. Stem 
cell factor, c-Kit ligand, potentiates the secondary wave of 
aggregation and serotonin secretion induced by ADP and epi- 
nephrine [29]. IL-6 enhances agonist-induced aggregation and 
secretion of thromboxane B 2 via a mechanism involving ara- 
chidonic acid metabolism [30]. Like TPO, these cytokines and 
growth factors described above do not induce aggregation by 
themselves. The aggregation enhancement byG-CSF, stem cell 
factor, and IL-6 is observed only in the secondary aggregation. 
In view of the fact that TPO potentiated not only the secondary 
aggregation but also the primary aggregation, TPO is unique. 
The mechanisms for the effects of TPO on platelet function 
must be different from those of other cytokines and growth 
factors. TPO might modulate platelet activation possibly 
through the tyrosine phosphorylation of proteins including 
JAKs and STATs which TPO can induce regardless of ASA 
treatment. Considering the clinical application of TPO for the 
future, it is important to evaluate the influence of in vivo TPO 
administration on platelet function as well as platelet produc- 
tion. 
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Fig. 5. Effect of TPO on ADP-induced aggregation fPRP pretreated 
with or without ASA. Citrated PRP was incubated with (+) or without 
(-) 1 mM ASA for 30 min. Aggregation was monitored using PRP 
treated with TPO (in ng/ml) or vehicle alone (-) for 3 min prior to the 
addition of ADP (in/zM). Each of symbols a and b in panel B shows 
two curves overlapped for ASA-treated or -untreated (+) platelets. 
Results are representative of five independent experiments with essen- 
tially similar results. 
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